Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Another Opinion: Exploring the market potential of FT218 (Avadel’s micropump sodium oxybate) in treating narcolepsy compared to existing therapies

Ticker(s): AVDL, JAZZ

Who's the expert?

Name: Dr Bharati Prasad - MD

Institution: University of Illinois

  • Medical Director of a 10 bed sleep lab; board certified in Pulmonary, Critical Care, and Sleep Medicine.
  • Manages ~4 patients with type 1 narcolepsy each week.
  • Familiar with FT218, JZP-110 and JZP-507 and has a special interest is sleep-disordered breathing and its relationship with cardiovascular disease.

Interview Questions

Please describe your clinical practice. How many patients with narcolepsy do you currently treat?

Added By: c_admin

Can you give us your thoughts on the trial design for FT218.

Added By: c_admin

How much of advantage is the one single dose before bedtime formulation of Avadel's micropump sodium oxybate? If approved, how likely would you be to switch patients to this drug?

Added By: c_admin

How well tolerated is JZP-110? What % of patient population would not be prescribed the drug due to side effects?

Added By: c_admin

How important do you find the lower levels of sodium in JZP-110? What % of your patient population is affected by the sodium content in traditional therapies? Do you see lower sodium as being a benefit?

Added By: c_admin

On a scale from 1-10, 10 being extremely excited where would you put your level of excitement for FT218?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.